IP Library Granted Patent US 8,604,076
Granted Patent B2
US 8,604,076 · App. 10/344,884 · Granted Dec 10, 2013

Method for producing a pharmaceutical composition comprising rotigotine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,604,076
App. No.
10/344,884
Granted
Dec 10, 2013
Kind
B2
Abstract

Pharmaceutical compositions are provided for administration of rotigotine in depot form. Pharmaceutical compositions of the invention can provide therapeutically significant plasma levels of rotigotine over a period of at least 24 hours after administration to a patient. Preferred pharmaceutical compositions of the invention include oily suspensions that contain rotigotine in solid form as well as anhydrous pharmaceutical compositions that comprise rotigotine.

Claims (11)

1. A method for producing an injectable pharmaceutical composition, comprising

preparing an oily suspension of solid-phase rotigotine or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable hydrophobic liquid phase that comprises a wetting agent free of phosphatides; and

thermally treating said oily suspension to provide a sterile depot suspension of said rotigotine or salt thereof.

2. The method of claim 1 , wherein less than 1% by weight of the rotigotine or salt thereof decomposes during the thermal treatment.

3. The method of claim 1 , wherein the solid-phase rotigotine or salt thereof is in crystalline form.

4. The method of claim 3 , wherein the crystalline rotigotine is in a form of a hydrochloride salt.

5. The method of claim 1 , wherein over 95% by weight of rotigotine in the composition is in solid phase.

6. The method of claim 1 , wherein less than 0.5% by weight of the rotigotine decomposes while thermally treating said oily suspension of rotigotine.

7. The method of claim 1 , wherein said thermally treating comprises autoclaving the composition.

8. The method of claim 1 , wherein said thermally treating is performed in a nitrogen atmosphere.

9. The method of claim 1 , wherein the oily suspension contains less than 3% water.

Assignments (3)
CORRECTIVE CHANGE OF NAME Recorded Apr 13, 2011
From: SCHWARZ PHARMA AG
To: UCB PHARMA GMBH
Reel/Frame 026132/0268 →
CHANGE OF NAME Recorded Feb 26, 2010
From: SCHWARZ PHARMA AG
To: UCB PHARMA GMBH
Reel/Frame 023985/0822 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2003
From: RIMPLER, STEPHAN; GRAPATIN, SABINE; KREIN, CLIFF; THELEN, MARKUS
To: SCHWARZ PHARMA AG
Reel/Frame 014055/0705 →